Wockhardt's Foviscu Antibiotic Shines in Phase 3 Trial for cUTI, Pyelonephritis

• Wockhardt's Foviscu antibiotic successfully met its primary endpoint in a Phase 3 clinical trial.
• The trial focused on complicated urinary tract infections (cUTI) and acute pyelonephritis caused by gram-negative bacteria.
• Foviscu achieved a 93.23% clinical cure rate, comparable to meropenem's 92.31%, demonstrating therapeutic equivalence.
• This marks Foviscu as Wockhardt's fifth proprietary antibiotic to complete a registration-enabling Phase 3 study.
• Foviscu offers a potential alternative to carbapenems, aiming to combat antimicrobial resistance and strengthen antibiotic stewardship.

Why It Matters: Wockhardt's Foviscu antibiotic showed strong efficacy in Phase 3 trials, offering a new tool against drug-resistant infections.